西医治疗抑郁症存在诸多难以克服的缺点，中医药以其“多靶点”和副作用小的优势越来越受到重视。我们前期已证实：柴胡疏肝散通过调节MAPKs信号通路和抑制HPA轴亢进发挥优于其拆方的抗抑郁作用。然而，其不能说明柴胡疏肝散配伍寻优的整体疗效，缺乏网络药理依据，因而成为本项目的关键科学问题。据此，我们基于中医整体观和网络药理学思想，提出柴胡疏肝散抗抑郁的整体疗效涉及蛋白-代谢分子群的网络调控。为证实这一假说，本项目拟从网络药理学角度，应用定量蛋白质-代谢组学技术，对柴胡疏肝散抗抑郁的配伍效应及其整体活性成分群进行研究，比较全方与基于治法进行拆方的整体疗效，获得其抗抑郁的多靶调整网络图及抗抑郁的活性靶成分群，从“组学”角度提供柴胡疏肝散整体疗效优于其拆方的理论依据。本研究将有助于揭示柴胡疏肝散“君臣佐使”抗抑郁的配伍优越性，明确其药效吸收靶成分谱，创新中药复方基础研究的新思路。

There are several disadvantages difficult to overcome for antidepression with western medicine, fortunately Chinese medicine to treat depression got more and more attention because of its "multi-target" efficacy and less side effects. We have pre-confirmed: Chaihu-Shugan-San (CHSGS) performed better antidepression than its demolition by regulating MAPKs signaling pathway and inhibition of the HPA axis hyperactivity. However, it is impossible to explain the overall effects of CHSGS as a whole formula, and it exists the lack of network pharmacology, thus above problems become the key scientific issues of this project. Accordingly, based the Chinese theory “whole concept” and network pharmacology thinking, we propose a hypothesis that the overall antidepressant efficacy of CHSGS refers to network regulation of proteins- metabolites. To confirm this hypothesis, based on the idea of network pharmacology, the project aims to apply quantitative proteomics-metabolomics technology to study antidepressant effect and the overall compatibility of the active ingredient group of CHSGS. to compare the overall effect and the effect of the demolition party to obtain a multi-target antidepressant network diagram and its anti-depressive compounds, according to the "omics" angle, to offer the evidence of better effects of CHSGS compared with theoretical basis demolition. This study will help to reveal the compatibility superiority of antidepressant effects of “Jun-Chen-Zuo-Shi” based CHSGS, to obtain absorption spectra of its efficacy target components, and to show an innovative new ideas for the basic research of traditional Chinese formula.